Table 2 Best overall response. SDC salivary duct carcinoma, AdCC adenoid cystic carcinoma.

From: PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab

 

All

SDC

AdCC

N = 27

(%)

(95%CI)

N = 15

(%)

(95%CI)

N = 6

(%)

(95%CI)

Complete response (CR)a

1

(3.7)

 

1

(6.7)

 

0

(0.0)

 

Partial response (PR)a

6

(22.2)

 

3

(20.0)

 

0

(0.0)

 

Stable disease (SD)

5

(18.5)

 

2

(13.3)

 

2

(33.3)

 

Progressive disease (PD)

15

(55.6)

 

9

(60.0)

 

4

(66.7)

 

Objective responseb

7

(25.9)

(11.1–46.3)

4

(26.7)

(7.8–55.1)

0

(0.0)

(0–45.9)

Clinical Benefitc

9

(33.3)

(16.5–54.0)

5

(33.3)

(11.8–61.6)

1

(16.7)

(0.4–64.1)

Disease controld

12

(44.4)

(25.5–64.7)

6

(40.0)

(16.3–67.7)

2

(33.3)

(4.3–77.7)

  1. (a) CR and PR are confirmed. (b) CR + PR. (c) CR + PR + SD over 24 weeks. (d) CR + PR + SD
Back to article page